Forecasting The Future: 5 Analyst Projections For Altimmune

In the latest quarter, 5 analysts provided ratings for Altimmune ALT, showcasing a mix of bullish and bearish perspectives.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $18.6, along with a high estimate of $25.00 and a low estimate of $12.00. A decline of 4.12% from the prior average price target is evident in the current average.

Understanding Analyst Ratings: A Comprehensive Breakdown

A clear picture of Altimmune's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Altimmune. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Altimmune compared to the broader market.
• Price Targets: Analysts predict movements in price targets, offering estimates for Altimmune's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

To gain a panoramic view of Altimmune's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Altimmune analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Altimmune: A Closer Look

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Altimmune: A Financial Overview

Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.

Revenue Growth: Altimmune's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -76.19%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Altimmune's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -487880.0%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Altimmune's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -13.29%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Altimmune's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -12.23%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Altimmune's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.